BioSpace News Archive

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced it will present full data results from the ESCaPE-CMD trial of Caladrius’s autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular Angiography and Interventions (“SCAI”) 2020 Scientific Sessions Virtu

A new study by Teladoc Health highlights the widespread negative mental health impact of the COVID-19 pandemic, the corresponding growing proactive support by employers to help meet the need, and the increased interest and comfort in virtual care options as part of American’s mental health and wellness.

CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment

NN, Inc., a diversified industrial company, announced that in response to the COVID-19 pandemic and the urgent need for personal protective equipment, Paragon Medical, a division of NN Life Sciences headquartered in Pierceton, Indiana, has designed and released an intubation shield for healthcare workers.

New leadership to guide the dental technology company’s expansion and commercialization

May 6, 2020 12:30 UTC Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the pu

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the availability of its 2019 Trinity Drug Index, a commercial analysis of 26 unique therapeutic agents approved in 2016.

DILIsym Services, Inc., a Simulations Plus company and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, announced that the U.S. Food and Drug Administration has again renewed its multi-seat license for the company’s leading quantitative systems toxicology modeling software, DILIsym®.

North American Partners in Anesthesia (NAPA) and MEDNAX, Inc. (NYSE: MD) today jointly announced the completion of NAPA’s acquisition of American Anesthesiology, a MEDNAX medical group, creating the destination of choice for anesthesia, pain management, and perioperative care in the United States.

SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA).